Drugmakers Merck and Moderna have released results from a new trial. The trial involves a personalized mRNA cancer vaccine. This vaccine has shown promise for preventing cancer recurrence.

The vaccine is described as a potential new tool against cancer. Results from the trial are considered promising.

Further details about the trial and vaccine are available from the source, including information about the potential of this new approach to cancer treatment.